Zydus Lifesciences on Thursday said the US health regulator has cautioned that its Gujarat-based injectables plant may be subject to regulatory actions.
The company said it has received a report from the US Food and Drug Administration (USFDA) for the inspection conducted at its injectables manufacturing facility located at Jarod, near Vadodara, Gujarat between April 15-23, 2024.
The USFDA has determined that the inspection classification of this facility is Official Action Indicated (OAI), it added.
According to FDA, OAI means “objectionable conditions were found and regulatory administrative sanctions by FDA are indicated” during the inspection.
“The company will work closely with the agency to resolve the regulatory status of this facility expeditiously,” the drug maker said.
Shares of Zydus Lifesciences settled marginally up at Rs 1,185.30 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First Published: Jul 18 2024 | 11:15 PM IST
